Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial

Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hormone research in paediatrics 2015-01, Vol.83 (5), p.321-331
Hauptverfasser: Bakker, N.E., Siemensma, E.P.C., Koopman, C., Hokken-Koelega, A.C.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 331
container_issue 5
container_start_page 321
container_title Hormone research in paediatrics
container_volume 83
creator Bakker, N.E.
Siemensma, E.P.C.
Koopman, C.
Hokken-Koelega, A.C.S.
description Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.
doi_str_mv 10.1159/000374113
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25764996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1686420070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</originalsourceid><addsrcrecordid>eNpd0cFu1DAQBmALgWhVeuCOkCUuIBGwncSJeyvL0laqBCqLOEZOPNm6dewwcVSW1-PF8Gq3e0A-eCR_Mxr5J-QlZx84L9VHxlheFZznT8gxlzLPRC3k00PN6yNyOk13bOvqSvHqOTkSZSULpeQx-fvZQtS4oUsPuN7QKx_1Pbynn4LZ0EUYxjDZaIOn2ht6A1O0fv1ol79H8MbGGYFaT78hjHMLGLWji1vrDIKnDzbephdtALOf1jlLv2-8wTAAbaEPqXM72My4nXuB4SHxy4BD8EBXCDoO4OMZPac3yYXB_gGT1vIRg3OpXKHV7gV51ms3wen-PiE_vixXi8vs-uvF1eL8OuvyvIgZcCMF54r1sixAC1b06XSqhl4WXdtr0KbgnepAdEbksq5bURrT1q3SSsguPyFvd3NHDL_m9BfNYKcOnNMewjw1XNayEIxVLNE3_9G7MKNP2yWlSlWxuhRJvdupDsM0IfTNiHZIaTScNdtwm0O4yb7eT5zbAcxBPkaZwKsduNe4BjyAff8_1IWrFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695970852</pqid></control><display><type>article</type><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</creator><creatorcontrib>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</creatorcontrib><description>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p &lt; 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>DOI: 10.1159/000374113</identifier><identifier>PMID: 25764996</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Body Composition - drug effects ; Body Composition - physiology ; Child ; Child, Preschool ; Diet ; Energy Intake - drug effects ; Energy Intake - physiology ; Energy Metabolism - drug effects ; Energy Metabolism - physiology ; Female ; Human Growth Hormone - pharmacology ; Human Growth Hormone - therapeutic use ; Humans ; Infant ; Male ; Motor Activity - drug effects ; Motor Activity - physiology ; Original Paper ; Prader-Willi Syndrome - drug therapy ; Prader-Willi Syndrome - physiopathology ; Treatment Outcome</subject><ispartof>Hormone research in paediatrics, 2015-01, Vol.83 (5), p.321-331</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>2015 S. Karger AG, Basel.</rights><rights>Copyright (c) 2015 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</citedby><cites>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25764996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bakker, N.E.</creatorcontrib><creatorcontrib>Siemensma, E.P.C.</creatorcontrib><creatorcontrib>Koopman, C.</creatorcontrib><creatorcontrib>Hokken-Koelega, A.C.S.</creatorcontrib><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><title>Hormone research in paediatrics</title><addtitle>Horm Res Paediatr</addtitle><description>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p &lt; 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</description><subject>Body Composition - drug effects</subject><subject>Body Composition - physiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diet</subject><subject>Energy Intake - drug effects</subject><subject>Energy Intake - physiology</subject><subject>Energy Metabolism - drug effects</subject><subject>Energy Metabolism - physiology</subject><subject>Female</subject><subject>Human Growth Hormone - pharmacology</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Motor Activity - physiology</subject><subject>Original Paper</subject><subject>Prader-Willi Syndrome - drug therapy</subject><subject>Prader-Willi Syndrome - physiopathology</subject><subject>Treatment Outcome</subject><issn>1663-2818</issn><issn>1663-2826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0cFu1DAQBmALgWhVeuCOkCUuIBGwncSJeyvL0laqBCqLOEZOPNm6dewwcVSW1-PF8Gq3e0A-eCR_Mxr5J-QlZx84L9VHxlheFZznT8gxlzLPRC3k00PN6yNyOk13bOvqSvHqOTkSZSULpeQx-fvZQtS4oUsPuN7QKx_1Pbynn4LZ0EUYxjDZaIOn2ht6A1O0fv1ol79H8MbGGYFaT78hjHMLGLWji1vrDIKnDzbephdtALOf1jlLv2-8wTAAbaEPqXM72My4nXuB4SHxy4BD8EBXCDoO4OMZPac3yYXB_gGT1vIRg3OpXKHV7gV51ms3wen-PiE_vixXi8vs-uvF1eL8OuvyvIgZcCMF54r1sixAC1b06XSqhl4WXdtr0KbgnepAdEbksq5bURrT1q3SSsguPyFvd3NHDL_m9BfNYKcOnNMewjw1XNayEIxVLNE3_9G7MKNP2yWlSlWxuhRJvdupDsM0IfTNiHZIaTScNdtwm0O4yb7eT5zbAcxBPkaZwKsduNe4BjyAff8_1IWrFg</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Bakker, N.E.</creator><creator>Siemensma, E.P.C.</creator><creator>Koopman, C.</creator><creator>Hokken-Koelega, A.C.S.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><author>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Body Composition - drug effects</topic><topic>Body Composition - physiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diet</topic><topic>Energy Intake - drug effects</topic><topic>Energy Intake - physiology</topic><topic>Energy Metabolism - drug effects</topic><topic>Energy Metabolism - physiology</topic><topic>Female</topic><topic>Human Growth Hormone - pharmacology</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Motor Activity - physiology</topic><topic>Original Paper</topic><topic>Prader-Willi Syndrome - drug therapy</topic><topic>Prader-Willi Syndrome - physiopathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakker, N.E.</creatorcontrib><creatorcontrib>Siemensma, E.P.C.</creatorcontrib><creatorcontrib>Koopman, C.</creatorcontrib><creatorcontrib>Hokken-Koelega, A.C.S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research in paediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakker, N.E.</au><au>Siemensma, E.P.C.</au><au>Koopman, C.</au><au>Hokken-Koelega, A.C.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</atitle><jtitle>Hormone research in paediatrics</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>83</volume><issue>5</issue><spage>321</spage><epage>331</epage><pages>321-331</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><abstract>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p &lt; 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>25764996</pmid><doi>10.1159/000374113</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1663-2818
ispartof Hormone research in paediatrics, 2015-01, Vol.83 (5), p.321-331
issn 1663-2818
1663-2826
language eng
recordid cdi_pubmed_primary_25764996
source MEDLINE; Karger Journals; Alma/SFX Local Collection
subjects Body Composition - drug effects
Body Composition - physiology
Child
Child, Preschool
Diet
Energy Intake - drug effects
Energy Intake - physiology
Energy Metabolism - drug effects
Energy Metabolism - physiology
Female
Human Growth Hormone - pharmacology
Human Growth Hormone - therapeutic use
Humans
Infant
Male
Motor Activity - drug effects
Motor Activity - physiology
Original Paper
Prader-Willi Syndrome - drug therapy
Prader-Willi Syndrome - physiopathology
Treatment Outcome
title Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T14%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dietary%20Energy%20Intake,%20Body%20Composition%20and%20Resting%20Energy%20Expenditure%20in%20Prepubertal%20Children%20with%20Prader-Willi%20Syndrome%20before%20and%20during%20Growth%20Hormone%20Treatment:%20A%20Randomized%20Controlled%20Trial&rft.jtitle=Hormone%20research%20in%20paediatrics&rft.au=Bakker,%20N.E.&rft.date=2015-01-01&rft.volume=83&rft.issue=5&rft.spage=321&rft.epage=331&rft.pages=321-331&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000374113&rft_dat=%3Cproquest_pubme%3E1686420070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695970852&rft_id=info:pmid/25764996&rfr_iscdi=true